Clinical trials · Michigan
Acute Leukemia clinical trials in Michigan
We’re tracking 42 recruiting acute leukemia studies with a site in Michigan — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Michigan
- NCT06124157RecruitingPhase 2
Targeted therapy plus chemo for children with Ph+ or Ph-like B-ALL
This trial tests if adding a targeted drug (dasatinib or imatinib) to a chemotherapy combination with blinatumomab works better for children and young adults with a specific genetic form of B-cell acute lymphoblastic leukemia. The goal is to see if this approach can improve treatment outcomes for patients with Philadelphia chromosome-positive or ABL-class Ph-like B-ALL.
Ann Arbor, MichiganAges 1 year–46 years - NCT07437950RecruitingPhase 2
Comparing treatment lengths for venetoclax in older adults with newly diagnosed acute myeloid leukemia
This study tests whether a shorter or longer course of the drug venetoclax works better for older adults with a type of blood cancer called acute myeloid leukemia (AML) who are not healthy enough for intensive chemotherapy. The goal is to find the best treatment duration to control the cancer while reducing side effects.
Brighton, MichiganAges 60 years+ - NCT07532525RecruitingPhase 1
Pomalidomide after CAR T for B-cell cancer
This trial tests whether the drug pomalidomide, given as a pill, can help people with B-cell leukemia or lymphoma who have recently received CAR T-cell therapy. The goal is to see if pomalidomide can keep the cancer from coming back, and it may be an option for those whose cancer is not growing but still needs management.
Ann Arbor, MichiganAges 18 years+ - NCT06317649RecruitingPhase 2
Venetoclax with hypomethylating agents for older or unfit adults with FLT3-mutated AML
This trial tests a combination of medicines (venetoclax and a hypomethylating agent) for people with acute myeloid leukemia (AML) who have a FLT3 mutation. It may be an option for older adults or those who cannot tolerate intensive chemotherapy.
Brighton, MichiganAges 18 years+ - NCT04546399RecruitingPhase 2
Blinatumomab with or without nivolumab for first relapse ALL
This study compares blinatumomab alone versus blinatumomab plus nivolumab in young people whose B-cell ALL has returned for the first time. It aims to see whether adding nivolumab improves control of the leukemia after relapse.
Royal Oak, MichiganAges 1–30 - NCT06672146RecruitingPhase 2
New treatments for AML with an IDH2 mutation
This trial tests new treatments for people with newly diagnosed acute myeloid leukemia (AML) that has a change in the IDH2 gene. It aims to find a better option for those who cannot have standard high-dose chemotherapy.
Brighton, MichiganAges 18 years+ - NCT06917911RecruitingPhase 2
Testing two drug additions to standard chemotherapy for a type of acute myeloid leukemia
This trial tests whether adding venetoclax or gemtuzumab ozogamicin to the usual chemotherapy helps people with a specific genetic type of acute myeloid leukemia (AML) respond better. It may improve chances of remission.
Brighton, MichiganAges 18–59 - NCT04972942RecruitingPhase 1
Immunotherapy for high-risk T-cell blood cancers after transplant
This Phase 1 study tests a targeted immune treatment given after strong pre-treatment (myeloablative chemo plus total-body radiation) before or along with an allogeneic stem cell transplant. It may help prevent the cancer from coming back in young people with high-risk T-cell ALL or certain T-cell lymphomas.
Grand Rapids, MichiganAges Up to 39 years - NCT04093570Enrolling by invitationPhase 2
Extension study for people continuing ASTX727 from a prior trial
This study checks whether continuing ASTX727 for people who already benefited from it in an earlier Taiho study is safe and effective. It may be an option if you stayed on ASTX727 at the end of your parent study and your doctor felt it was helping you.
Grand Rapids, MichiganAges 18 years+ - NCT07007312RecruitingPhase 3
Ziftomenib plus standard chemo for certain AML patients
This trial tests a new drug, ziftomenib, added to standard chemotherapy for adults with untreated acute myeloid leukemia (AML) who have specific gene changes (NPM1 mutation or KMT2A rearrangement). It aims to see if the combination works better than standard treatment alone.
Ann Arbor, MichiganAges 18 years+ - NCT02074839RecruitingPhase 1
Oral AG-120 for advanced blood cancers with an IDH1 mutation
This Phase 1 study tests an oral medicine called AG-120 in adults with advanced blood cancers that have a specific IDH1 mutation. It also looks at safety and how the treatment works, with frequent blood, urine, and bone marrow samples.
Detroit, MichiganAges 18 years+ - NCT06395103RecruitingPhase 1/Phase 2
Zilovertamab vedotin for blood cancers and solid tumors
This trial tests a new drug called zilovertamab vedotin for children and young adults with certain blood cancers or solid tumors. The drug is designed to target and kill cancer cells, and the study will see if it is safe and effective.
Grand Rapids, MichiganAges 6 months–25 years - NCT05554393RecruitingPhase 2
Treating intermediate-risk AML in younger adults
This trial compares three different drug combinations for younger adults (18-59) with intermediate-risk AML. You will be assigned to one of three groups: standard chemotherapy (cytarabine + daunorubicin), that same chemotherapy plus venetoclax, or venetoclax combined with azacitidine.
Brighton, MichiganAges 18–59 - NCT05429632RecruitingPhase 3
Mocravimod to prevent relapse after bone marrow transplant for AML
This Phase 3 trial tests mocravimod, added to standard care, to help keep acute myeloid leukemia (AML) from coming back after an allogeneic bone marrow (stem cell) transplant. It may help by supporting long-term remission during the transplant recovery period.
Grand Rapids, MichiganAges 18–75 - NCT05082519RecruitingPhase 2
Calorie restriction and exercise to improve leukemia treatment in young patients
This study tests whether a special diet (calorie restriction) and increased physical activity can make chemotherapy work better for young people with B-ALL. Participants will follow a monitored diet and exercise plan during their first month of treatment.
Ann Arbor, MichiganAges 7–25 - NCT04293562RecruitingPhase 3
Comparing chemotherapy options for newly diagnosed AML in young patients
This trial compares standard chemotherapy with newer drug combinations (CPX-351 and gilteritinib) for children and young adults with acute myeloid leukemia (AML), a type of blood cancer. It aims to find which treatment works better and who might benefit from targeted therapy based on specific genetic changes (FLT3 mutations).
Royal Oak, MichiganAges 6 months–21 years - NCT03509961RecruitingPhase 2
Reducing total body radiation for children with leukemia transplants
This study looks at whether some children and young adults with B-ALL can safely get a transplant without total body irradiation (TBI), based on special leukemia test results. It’s meant to help lower radiation-related risks while keeping leukemia control strong.
Grand Rapids, MichiganAges 1–25 - NCT07751991RecruitingPhase 1
Study of a new drug for relapsed AML with specific genetic changes
This trial tests a new drug for people with acute myeloid leukemia (AML) that has come back or hasn't responded to standard therapies, and whose leukemia has certain genetic markers. The drug may target these specific changes to help stop the cancer.
Grand Rapids, MichiganAges 18 years+
Acute Leukemia trials by city in Michigan
Where these studies are running in Michigan
Institutions with a site for the recruiting acute leukemia studies listed above.
- Trinity Health Brighton · 5 studies
- Trinity Health IHA Medical Group Hematology Oncology - Canton · 5 studies
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital · 5 studies
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus · 5 studies
- Trinity Health Saint Joseph Mercy Oakland Hospital · 5 studies
- Trinity Health Saint Mary Mercy Livonia Hospital · 5 studies
- Henry Ford Health · 4 studies
- Allegiance Health · 3 studies
What taking part in a acute leukemia study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Acute Leukemia trials in other states
Common questions
- Are there acute leukemia clinical trials in Michigan?
- Yes. We're currently tracking 42 recruiting acute leukemia studies with a site in Michigan, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a acute leukemia study in Michigan?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Michigan to take part?
- Not necessarily. These studies have a site in Michigan, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a acute leukemia trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New acute leukemia studies open in Michigan regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.